PanOph

Corneal Dystrophies

Cornea

1. Corneal Dystrophies

  • Definition: Corneal dystrophies are usually bilateral, symmetric, slowly progressive, inherited, non-inflammatory disorders affecting the cornea.
  • They may cause progressive corneal opacity involving one or more corneal layers; progression and the degree of opacity vary by dystrophy.
  • They are usually unrelated to environmental factors or systemic disease, although exceptions occur.
  • Age at onset varies by dystrophy: some present in childhood or the first or second decade, whereas others present during adulthood.
  • The International Committee for Classification of Corneal Dystrophies (IC3D) provides a classification framework for corneal dystrophies.
Exam pearl
  • Clinical Analogy: Think of the cornea as a five-layered glass pane. Each dystrophy is a manufacturing defect in one specific layer - some leave fingerprints on the surface (epithelial), some imprint patterns within the lamination (stromal), and some corrode the back coating (endothelial). The location of the smudge tells you which layer's gene has misfired.

Defining Features (Mnemonic: B-S-N-G-P)

  • Bilateral and largely symmetrical
  • Slow, progressive opacification
  • Non-inflammatory at onset (secondary inflammation may occur from erosions)
  • Genetically determined - most are autosomal dominant
  • Primarily corneal; systemic associations can occur in some dystrophies, including Schnyder corneal dystrophy, which is generally considered a local corneal lipid-metabolism disorder despite reported systemic hypercholesterolemia.

2. IC3D Classification

  • The IC3D system revised the traditional anatomy-based classification by integrating phenotypic, pathologic, and genetic information and assigning evidence categories (1–4).
  • Category 1 is well-defined with a known gene; Category 4 is a suspected new dystrophy.
  • Anatomically, dystrophies are grouped by the corneal layer principally affected.
GroupLayer AffectedExamples (high-yield)
• Epithelial & Subepithelial• Epithelium • Basement membrane • Subepithelial tissue• Epithelial Basement Membrane Dystrophy (EBMD) / Cogan / Map-Dot-Fingerprint • Meesmann • Lisch • Subepithelial Mucinous • Gelatinous drop-like corneal dystrophy
• Epithelial-Stromal Transforming Growth Factor Beta-Induced (TGFBI)• Epithelium and stroma • May involve multiple corneal layers• Reis-Bucklers (corneal dystrophy Bowman layer 1 [CDB1]) • Thiel-Behnke (corneal dystrophy Bowman layer 2 [CDB2]) • Lattice type 1 (lattice corneal dystrophy type 1 [LCD1]) • Granular type 1 & 2 (Avellino)
• Stromal• Stroma• Macular (macular corneal dystrophy [MCD]) • Schnyder (Schnyder corneal dystrophy [SCD]) • Congenital Stromal corneal dystrophy • Fleck • Posterior Amorphous corneal dystrophy • Central cloudy dystrophy of François (central cloudy dystrophy of François [CCDF]) • Pre-Descemet corneal dystrophy
• Endothelial• Endothelium• Fuchs Endothelial Corneal Dystrophy (FECD) • Posterior Polymorphous corneal dystrophy (PPCD) • Congenital Hereditary Endothelial Dystrophy (CHED) • X-linked Endothelial corneal dystrophy (XECD)
Exam pearl
  • Pearl: Most transforming growth factor beta-induced (TGFBI) dystrophies (Reis-Bucklers, Thiel-Behnke, lattice type 1, granular 1, granular 2/Avellino) map to chromosome 5q31 - a classic exam crossover question.

The TGFBI Gene - Why It Matters

  • The transforming growth factor beta-induced (TGFBI) gene on 5q31 codes for keratoepithelin, an extracellular matrix protein.
  • Different missense mutations produce different phenotypes despite involving the same gene - a beautiful example of phenotypic heterogeneity:
MutationPhenotypeDeposit TypeStain
• R124L• Reis-Bücklers corneal dystrophy• Rod-shaped (electron microscopy)• Masson trichrome (red)
• R555Q• Thiel-Behnke corneal dystrophy• Curly fibres (electron microscopy)• Masson trichrome
• R124C• Lattice corneal dystrophy type 1• Amyloid• Congo red → birefringence with red-green dichroism under polarized light
• R555W• Granular corneal dystrophy type 1• Hyaline• Masson trichrome (red)
• R124H• Avellino corneal dystrophy / granular corneal dystrophy type 2• Hyaline + amyloid• Masson trichrome and/or Congo red
Exam pearl
  • • Avellino = Granular + Lattice features. • Named after Avellino, Italy. • Critical because patients undergoing laser-assisted in situ keratomileusis (LASIK) with this mutation develop accelerated deposition along the flap interface. • Hence pre-laser-assisted in situ keratomileusis (LASIK) genetic awareness in endemic populations (Korea).

3. Epithelial & Subepithelial Dystrophies

Epithelial Basement Membrane Dystrophy (EBMD / Cogan / Map-Dot-Fingerprint)

Most common anterior corneal dystrophy. Most cases are sporadic and may be age-related; autosomal-dominant inheritance occurs in some families. Transforming growth factor beta-induced (TGFBI) mutations occur in a subset of patients.

Pathology
  • Reduplication of epithelial basement membrane into stroma
  • Intraepithelial extension of epithelial basement membrane forming microcysts (dots)
  • Defective hemidesmosome attachment → recurrent corneal erosions (RCE)
Clinical Features
  • Three patterns on retroillumination/sclerotic scatter:
  • Maps (geographic grey patches)
  • Dots (Cogan microcysts)
  • Fingerprints (concentric lines)
  • About 10% develop painful recurrent corneal erosions (RCE).
  • Symptoms classically wake patient on opening eyes (eyelid sticks to loose epithelium)
Management
  • Lubricants (preservative-free) + hypertonic 5% NaCl ointment at night
  • Bandage contact lens for acute erosion with topical antibiotic prophylaxis
  • Definitive treatment after failed conservative therapy:
  • Epithelial debridement + diamond burr polishing of Bowman's
  • Anterior stromal puncture (ASP) for peripheral lesions
  • Phototherapeutic keratectomy (PTK) for central or refractory cases
  • Oral doxycycline 50 mg twice daily + topical steroid - inhibits matrix metalloproteinase-9 (MMP-9) and reduces erosion frequency

Meesmann Epithelial Dystrophy

  • Autosomal dominant.
  • Genes: KRT3 (12q) or KRT12 (17q) - keratin 3/12 pair.
  • Onset in early childhood.
  • Myriad tiny clear intraepithelial cysts, best seen on retroillumination ('whorled' pattern)
  • Cysts contain amorphous material probably composed of degenerated epithelial cells.
  • The intracytoplasmic “peculiar substance” consists of fibrogranular material surrounded by tangles of cytoplasmic filaments.
  • Generally asymptomatic; may cause irritation, photophobia, foreign-body sensation or tearing, and painful recurrent epithelial erosions.
  • Palliative treatment includes ocular lubricants.
  • Severe symptomatic disease may require epithelial debridement or phototherapeutic keratectomy (PTK), with lamellar keratoplasty advocated in selected severe cases.

Lisch Epithelial Corneal Dystrophy

X-linked dominant. Gene locus Xp22.3.

  • Whorled, feathery, grey opacities arranged in band-like or radial patterns
  • Best seen on retroillumination (densely crowded clear vacuoles)
  • Vision usually unaffected; visual-axis involvement may cause blurred vision and may require superficial keratectomy

4. Epithelial-Stromal TGFBI Dystrophies

Reis-Bücklers corneal dystrophy type 1 (CDB1) vs Thiel-Behnke corneal dystrophy type 2 (CDB2)

FeatureReis-Bücklers corneal dystrophy type 1 (CDB1)Thiel-Behnke corneal dystrophy type 2 (CDB2)
Mutation in transforming growth factor beta-induced (TGFBI)R124LR555Q
Layer• Bowman’s replaced by sheet-like granular Masson trichrome–red deposits• Bowman’s replaced by superficial fibrocellular pannus with a wavy sawtoothed pattern
Pattern• Confluent irregular geographic-like opacities• Symmetrical subepithelial honeycomb opacities
Electron microscopy hallmarkRod-shaped bodiesCurly fibres (9–15 nm)
Severity• More severe; visual loss earlier• Milder; later visual loss
Recurrent corneal erosions• Frequent and painful• Less frequent
Recurrence after penetrating keratoplasty• Frequent recurrence; median time to simple recurrence approximately 2 years• Lower; later
Treatment of choice• Phototherapeutic keratectomy (PTK) preferred over lamellar keratoplasty• Phototherapeutic keratectomy (PTK) is the treatment of choice when the opacity is not deeper than one-third of the cornea • If phototherapeutic keratectomy (PTK) is not feasible, lamellar keratectomy or keratoplasty may be considered
Exam pearl
  • Both replace Bowman's layer, but electron microscopy (EM) distinguishes them definitively histopathologically. Rod = Reis (mnemonic: Rod for Reis). Curly = Thiel-Behnke.

Granular Corneal Dystrophy (GCD)

Autosomal dominant; transforming growth factor beta-induced (TGFBI) gene at 5q31. Two main types:

  • Type 1: Discrete crumb/breadcrumb-shaped grey-white hyaline deposits, initially in superficial/anterior stroma, separated by clear stroma. Opacities may involve peripheral stroma but do not extend to the limbus. Onset in childhood.
  • Type 2: Superficial whitish dots and round patches with moth-eaten centres; spiky anterior-to-midstromal deposits may be star-, icicle-, or spider-shaped. Histopathology shows both hyaline and amyloid deposits; the amyloid component does not typically resemble classic lattice lines.
  • Type 3: Granular corneal dystrophy type 3 is a former alternative name for Reis-Bücklers corneal dystrophy, classified as corneal dystrophy of Bowman layer type I.
  • Granular corneal dystrophy type 2 is exacerbated after laser-assisted in situ keratomileusis, with accelerated opacification; laser-assisted in situ keratomileusis is strongly contraindicated.
Histology Pearl
  • Granular corneal dystrophy deposits contain hyaline protein and stain red with Masson trichrome.
  • Lattice deposits contain amyloid and stain with Congo red, showing apple-green birefringence under polarized light.
  • Macular deposits contain glycosaminoglycans and stain with colloidal iron or Alcian blue.

Pearl: Mnemonic for stains: 'GHM - Granular Hyaline Masson, Lattice Amyloid Congo, Macular Mucopolysaccharide Alcian'

Lattice Corneal Dystrophy (LCD)

TypeGeneInheritanceSystemicKey Feature
Lattice corneal dystrophy type 1 (LCD1; Biber-Haab-Dimmer)• Transforming growth factor beta-induced (TGFBI) R124C• Autosomal dominant (AD)• None• Classic refractile branching lines • Central haze
Lattice corneal dystrophy type 2 (LCD2; Meretoja syndrome; familial amyloidosis, Finnish type)• Gelsolin (GSN), chromosome 9q32–q34• Autosomal dominant (AD)• Yes • Cranial neuropathy • Mask facies • Cutis laxa• Sparse peripheral lattice • Mild visual loss • Relatively preserved visual acuity for longer
Historical lattice corneal dystrophy type III / type IIIA• Transforming growth factor beta-induced (TGFBI) • The P501T mutation is specifically reported for historical type IIIA• Autosomal dominant (AD) for historical type IIIA • Historical type III is a distinct entity and should not be combined with type IIIA• None for the transforming growth factor beta-induced (TGFBI)-associated historical type IIIA variant• Delayed onset • Thicker, limbus-to-limbus ropy lines
Granular corneal dystrophy type 2 (GCD2; formerly Avellino dystrophy)• Transforming growth factor beta-induced (TGFBI) R124H• Autosomal dominant (AD)• None• Mixed granular and lattice-like deposits • The lines differ from classic lattice corneal dystrophy lines and rarely form a true crisscross lattice configuration
  • Pathology: Amyloid deposits in stroma (Congo red, apple-green birefringence, metachromasia with crystal violet, fluorescence with thioflavin T). Recurrent corneal erosion is frequent; visual impairment occurs by the fourth decade.
  • Meretoja syndrome is systemic amyloidosis with corneal findings (lattice corneal amyloidosis); the former term lattice corneal dystrophy type 2 is a misnomer. Mutant gelsolin-derived amyloid deposits occur in the cornea and other affected tissues; cranial neuropathy causes facial nerve palsy. Other manifestations include blepharochalasis, dry skin, and peripheral polyneuropathy. Important: this is a hereditary systemic gelsolin amyloidosis, not a corneal dystrophy.

5. Stromal Dystrophies

Macular Corneal Dystrophy (MCD; Groenouw corneal dystrophy type II)

  • Autosomal recessive (AR) - the only common autosomal-recessive stromal dystrophy.
  • Gene: CHST6 (chromosome 16q22) encoding corneal N-acetylglucosamine-6-O-sulfotransferase.
  • Defective sulfation of keratan sulfate → accumulation of unsulfated glycosaminoglycans (GAGs).
TypeSerum Antigenic Keratan SulfateCornea Keratan Sulfate
• Type I (most common)• Absent• Absent
• Type IA• Absent in serum• Present in keratocytes only
• Type II• Normal or lower levels• All abnormal deposits react positively with antigenic keratan sulfate

Clinical Features

  • Onset in childhood; severe visual impairment between 10 and 30 years
  • Initially central, superficial, irregular whitish fleck-like opacities; later may extend to the limbus and deep stroma, with progressive diffuse stromal haze
  • Diffuse, ill-defined grey-white opacities with intervening cloudy stroma (in contrast to the clear intervening stroma typical of granular corneal dystrophy)
  • Thinner cornea than normal (contrast with Fuchs endothelial corneal dystrophy, which can cause corneal edema and swelling)
  • Photophobia and painful recurrent corneal erosions can rarely occur

Management

  • Observation is appropriate for asymptomatic or minimally symptomatic disease.
  • Topical treatment is mainly symptomatic and has a limited role in removing stromal deposits.
  • Treatment is guided by dystrophy type, symptoms, visual impairment, deposit depth, and endothelial status.
  • Phototherapeutic keratectomy (PTK) has a limited role in deep stromal involvement; selected superficial disease may have temporary visual improvement, but recurrence is possible.
  • Visually significant deep or advanced opacification may require penetrating keratoplasty (PK) or deep anterior lamellar keratoplasty (DALK).
  • Deep anterior lamellar keratoplasty (DALK) is technically challenging when stromal deposits extend deeply toward or involve Descemet membrane; procedure selection depends on the dystrophy and the status of Descemet membrane and endothelium.
  • Recurrence after keratoplasty varies by dystrophy and surgical depth; preserving a clear Descemet membrane does not eliminate recurrence, particularly when diseased host stroma remains.
  • Recurrence may require repeat treatment or corneal transplantation.
Exam pearl
  • Macular corneal dystrophy (MCD) = murky stroma between deposits → may require penetrating keratoplasty (PK). Three M's.
  • The cornea is thin and cloudy throughout, unlike granular corneal dystrophy, which has discrete deposits in clear stroma.

Schnyder Crystalline Dystrophy (SCD)

Autosomal dominant (AD). Gene: UBIAD1 (1p36). Defect in cholesterol metabolism. Systemic lipid abnormalities, including hyperlipoproteinaemia, may occur in affected and unaffected family members.

  • Corneal crystals are present in approximately 50% of patients.
  • Noncrystalline central opacity or haze may occur in the remainder.
  • Age-related progression may lead to arcus lipoides and midperipheral panstromal haze.
  • Arcus lipoides is typically noted between 23 and 38 years and becomes more prominent with progression.
  • Decreased corneal sensation, particularly with age, may result from disruption of the basal epithelial/subepithelial nerve plexus by corneal deposits.
  • Glare increases, and photopic vision may be disproportionately reduced compared with scotopic vision.
  • Evaluate for systemic hypercholesterolaemia or hyperlipoproteinaemia; a fasting lipid profile may be obtained when clinically indicated.
  • Phototherapeutic keratectomy (PTK) can be performed for symptomatic crystals in the visual axis.
  • Deep anterior lamellar keratoplasty (DALK) or penetrating keratoplasty (PK) may be required for visually limiting panstromal lipid deposits.
  • Evaluate and manage systemic lipid abnormalities for cardiovascular risk; corneal deposits may persist or recur despite treatment.

Other Stromal Dystrophies (Quick Reference)

DystrophyInheritanceGeneHallmark
Congenital stromal corneal dystrophyAutosomal dominantDCN (decorin)• Diffuse flaky stromal opacities at birth • Thick cornea • Non-progressive or slowly progressive
Fleck dystrophy (François-Neetens)Autosomal dominantPIKFYVE• Discrete gray-white dandruff-like flecks throughout an otherwise clear stroma • Usually asymptomatic • Slight photophobia or decreased corneal sensitivity may occur
Posterior amorphous corneal dystrophyAutosomal dominantRegion 12q21.33• Sheet-like grey opacities in the posterior stroma • Flat cornea (low keratometry)
Central cloudy dystrophy of FrançoisUnknown; autosomal-dominant inheritance occasionally reportedNo gene or genetic locus identified• Central polygonal or rounded stromal opacities surrounded by clear tissue • Mostly asymptomatic • Indistinguishable from posterior crocodile shagreen degeneration
Pre-Descemet corneal dystrophyNo definite inheritance pattern; punctiform and polychromatic subtype reported as autosomal dominant in one pedigreeUnknown when isolated• Focal, fine, polymorphic grey opacities immediately anterior to Descemet membrane • Usually begins after 30 years • Vision is usually unaffected and patients are asymptomatic • Some forms progress

6. Endothelial Dystrophies

Fuchs Endothelial Corneal Dystrophy (FECD)

  • The most clinically important endothelial dystrophy.
  • Bilateral, slowly progressive.
  • Women, usually presenting in the fifth to sixth decades (female-to-male ratio approximately 2.5–3:1).
Genetics
  • Early-onset: COL8A2 mutations (rare, autosomal dominant (AD)).
  • Late-onset (typical): TCF4 gene on chromosome 18.
  • An intronic trinucleotide cytosine-thymine-guanine (CTG) repeat expansion (>50 repeats) is a major known genetic risk factor; it is reported in approximately 70–80% of Fuchs endothelial corneal dystrophy cases in many predominantly European cohorts.
  • Other reported loci: SLC4A11; ZEB1 and LOXHD1 have been reported, but their causal roles remain unconfirmed or conflicting.

Pathophysiology

Endothelial cell dysfunction → oxidative stress, mitochondrial dysfunction, accumulation of abnormal extracellular matrix as guttae on Descemet's membrane → progressive endothelial cell loss → stromal oedema → epithelial bullae.

Clinical Stages (Krachmer)
Clinical Stages (Krachmer)
StageFindingsSymptoms
1• Central guttae (>12 nonconfluent) • No oedema• Asymptomatic
2• Beaten-metal appearance of Descemet's • Mild stromal oedema• Morning blurring • Glare
3• Bullous keratopathy • Epithelial oedema • Bullae• Pain on bullae rupture • Photophobia
4• Subepithelial fibrosis (pannus) • Stromal scarring • Peripheral superficial or deep vascularisation• Progressive visual loss

Investigations

Investigations
  • Specular microscopy: Reduced cell density, increased polymegethism (coefficient of variation) and pleomorphism (hexagonality), guttae as dark bodies with bright centres
  • Confocal microscopy: Visualises guttae, useful when corneal oedema obscures specular microscopy
  • Pachymetry: Increased central corneal thickness may indicate corneal oedema and should be interpreted with clinical findings and tomographic patterns; in advanced disease, thickness may be greater immediately after awakening and decrease during the first hours
  • Scheimpflug (Pentacam) posterior elevation and pachymetry maps: Focal posterior surface depression, loss of regular isopachs, and displacement of the thinnest point may indicate subclinical oedema; the combined map pattern helps predict Fuchs endothelial corneal dystrophy progression or need for endothelial keratoplasty
  • Anterior segment optical coherence tomography (AS-OCT): Measures corneal thickness and oedema-related structural changes; may support assessment before or after endothelial surgery

Management

Management
  • Conservative: Hypertonic sodium chloride 5% drops or ointment; a hair-dryer may cautiously increase evaporation and reduce morning oedema. Treat elevated intraocular pressure when clinically indicated; no universal low-normal target is established for this purpose.
  • Surgical decision-making: Consider endothelial keratoplasty when corneal oedema and visually significant symptoms impair function. Before cataract surgery, central corneal thickness greater than 640 µm, endothelial cell density below 1,000 cells/mm², or microcystic oedema increases concern for postoperative decompensation and may support combined cataract surgery and endothelial keratoplasty.
  • Procedure of choice in suitable eyes today: Descemet membrane endothelial keratoplasty (DMEK) generally provides faster or better visual recovery and lower graft-rejection risk than Descemet stripping automated endothelial keratoplasty (DSAEK), although outcomes and rejection rates vary by study and follow-up.
  • Descemet stripping automated endothelial keratoplasty (DSAEK): Still useful when complex anterior segment, glaucoma tubes, aphakia
  • Penetrating keratoplasty: Consider when significant stromal scarring or other full-thickness corneal pathology limits visual rehabilitation with endothelial keratoplasty.
  • Combined phacoemulsification plus Descemet membrane endothelial keratoplasty (DMEK) ('triple') in cataract co-existence - single anaesthetic

Evolving Concepts - The Future of Fuchs Endothelial Corneal Dystrophy Care

  • Descemet stripping only (DSO) / Descemetorhexis without endothelial keratoplasty (DWEK): Selective removal of approximately 4 mm of central Descemet membrane may be considered in carefully selected patients with central confluent guttae, healthy peripheral endothelium, no clinically evident bullous keratopathy, and no major ocular comorbidity. Success is variable; in a preliminary series, corneal clarity was achieved in 4 of 5 eyes, with possible stromal opacity and irregular astigmatism.
  • Rho-associated protein kinase inhibitors, including ripasudil, may promote endothelial wound healing and can be used as adjuncts after Descemet stripping only in selected cases. The Descemet Endothelial Thickness Comparison Trial II is evaluating Descemet stripping only with adjunctive ripasudil; a doubled success rate has not been established.
  • Cell-injection therapy: Cultured human corneal endothelial cells supplemented with a rho-associated protein kinase inhibitor were injected intracamerally in a phase I clinical trial; the study reported increased endothelial cell density in 11 treated eyes with bullous keratopathy.
  • Antisense oligonucleotides targeting the transcription factor 4 (TCF4) cytosine-thymine-guanine (CTG) repeat are an investigational preclinical strategy.
Exam pearl
  • An asymmetric S-stamp on the Descemet membrane endothelial keratoplasty (DMEK) graft helps avoid upside-down implantation.
  • Air or 20% sulfur hexafluoride (SF6) tamponade may be used.
  • Supine (face-up) positioning postoperatively; evidence for prolonged strict positioning is mixed.
  • Rebubble rates after Descemet membrane endothelial keratoplasty (DMEK) vary substantially by series and protocol; avoid stating a universal 10–15% rate.
  • At 1 year, endothelial cell loss after Descemet membrane endothelial keratoplasty (DMEK) is commonly reported in the approximate 30–36% range, with substantial variation among studies; comparative evidence with Descemet stripping automated endothelial keratoplasty (DSAEK) is mixed.

Posterior Polymorphous Corneal Dystrophy (PPCD)

  • Autosomal-dominant (AD); bilateral but often asymmetric.
  • Genes: ZEB1 (TCF8) is an established association; VSX1 and COL8A2 have been reported or proposed, but their causal association remains disputed or insufficiently supported.
  • Defect in endothelial transition → cells become epithelial-like with desmosomes and microvilli.
  • Vesicles (single or grouped lesions).
  • Bands (railroad tracks with scalloped edges).
  • Diffuse opacities.
  • Often asymptomatic; a subset progresses to corneal decompensation.
  • Strong association with iridocorneal anomalies.
  • Glaucoma or elevated intraocular pressure occurs in approximately 15%–35% of cases.
  • Posterior polymorphous corneal dystrophy may be associated with Alport syndrome; Alport syndrome is caused by variants in COL4A3, COL4A4, or COL4A5 and may include renal disease and sensorineural hearing loss. This association should not be attributed to ZEB1 mutation.
  • Corneal decompensation → endothelial keratoplasty (EK), including Descemet membrane endothelial keratoplasty (DMEK) or Descemet stripping automated endothelial keratoplasty (DSAEK), or penetrating keratoplasty (PK).
  • Pearl: PPCD on slit lamp: 'Railroad-track-like' bands with scalloped edges at the level of Descemet's are pathognomonic.
  • Always check intraocular pressure (IOP) and gonioscopy - corectopia, iris atrophy, and peripheral anterior synechiae may occur.

Congenital Hereditary Endothelial Dystrophy (CHED)

FeatureCongenital hereditary endothelial dystrophy (CHED; formerly CHED2)Historical congenital hereditary endothelial dystrophy (CHED1; reclassified as posterior polymorphous corneal dystrophy [PPCD])
InheritanceAutosomal recessiveAutosomal dominant
GeneSLC4A11 (20p13)Now considered posterior polymorphous corneal dystrophy (PPCD) spectrum
OnsetAt birth / infancyChildhood, slowly progressive
Cornea• Diffuse ground-glass oedema • 2–3× normal thickness • Nystagmus may be present, especially with severe corneal opacification-
Photophobia/TearingUsually absent or minimal-
Intraocular pressure• Usually normal • Readings may be artifactually high because of corneal thickening • Assess for glaucoma-
  • Differential diagnosis: Congenital glaucoma (raised intraocular pressure, buphthalmos, photophobia, Haab's striae).
  • Differential diagnosis: Birth trauma (unilateral, vertical Descemet's tears).
  • Differential diagnosis: Congenital rubella (cataract, deafness, cardiac disease).
  • Differential diagnosis: Mucopolysaccharidosis (systemic features).
  • Congenital hereditary endothelial dystrophy → penetrating keratoplasty or Descemet stripping automated endothelial keratoplasty/Descemet membrane endothelial keratoplasty in a pediatric eye - challenging due to a soft eye and shallow anterior chamber.
  • Pearl: Harboyan syndrome = congenital hereditary endothelial dystrophy with progressive sensorineural deafness (also SLC4A11).
  • Must do audiometry in any child with congenital hereditary endothelial dystrophy.

X-linked Endothelial Corneal Dystrophy (XECD)

  1. Inheritance & locus: X-linked dominant; locus Xq25
  2. Affected males: Congenital corneal clouding, ranging from diffuse haze to ground-glass/milky opacity; nystagmus may occur.
  3. Carrier females: mild moon-crater endothelial changes, often asymptomatic
  4. Treatment: Penetrating keratoplasty (PK) may be required for visually significant corneal opacity; management is individualized because of the rarity of the disorder.

7. Histopathology & Stains - Master Table

DystrophyDepositLayerDiagnostic StainElectron microscopy (EM)/Special findings
Reis-Bücklers• Hyaline (mutant transforming growth factor beta-induced protein (TGFBIp))• Bowman’s layer• Masson trichrome (red)• Rod-shaped bodies
Thiel-Behnke• Hyaline• Bowman’s layer• Masson trichrome• Curly fibers (9–15 nanometres)
Granular corneal dystrophy type 1 (GCD1)• Hyaline• Anterior stroma• Masson trichrome (red)• Rod-shaped bodies or trapezoid bodies
Lattice corneal dystrophy (LCD)• Amyloid• Stroma• Congo red with apple-green birefringence under polarized light • Thioflavin T• Crystal-violet metachromasia
Avellino (granular corneal dystrophy type 2 (GCD2))• Hyaline • Amyloid• Stroma• Masson trichrome • Congo red• Both features
Macular corneal dystrophy• Glycosaminoglycans (keratan sulfate)• Full stroma • Endothelium • Descemet’s membrane• Alcian blue • Colloidal iron• Keratocytes and endothelial cells: vacuoles and lamellar bodies • Thin cornea
Schnyder corneal dystrophy• Cholesterol • Phospholipids• Epithelium • Bowman’s layer • Stroma• Oil Red O (frozen tissue) • Filipin• Lipid deposits on electron microscopy (EM) • Crystals may be absent
Fuchs endothelial corneal dystrophy (FECD)• Guttae on thickened Descemet’s membrane• Descemet’s membrane• Periodic acid–Schiff (PAS)-positive• Sparse and atrophic endothelial cells • Posterior basement membrane-like material on transmission electron microscopy (TEM)
Macular corneal dystrophy versus other dystrophies• Glycosaminoglycans (GAGs) in keratocytes and endothelial cells (intracytoplasmic)• -• Alcian blue• Also extracellular deposits in stroma and Descemet’s membrane

8. Surgical Decision-Making Flowchart

  • Anterior dystrophies (Bowman's / anterior stroma): Phototherapeutic keratectomy (PTK) first; anterior lamellar keratoplasty (ALK) / deep anterior lamellar keratoplasty (DALK) if deeper; penetrating keratoplasty (PK) rarely.
  • Macular corneal dystrophy (MCD) without Descemet membrane or endothelial involvement: deep anterior lamellar keratoplasty (DALK) is a viable option that avoids endothelial graft rejection.
  • Macular corneal dystrophy (MCD) with Descemet membrane or endothelial involvement: penetrating keratoplasty (PK) is considered.
  • Endothelial dystrophies (Fuchs endothelial corneal dystrophy (FECD), posterior polymorphous corneal dystrophy (PPCD), congenital hereditary endothelial dystrophy (CHED)): endothelial keratoplasty (EK) is the gold standard.
  • Routine Fuchs endothelial corneal dystrophy (FECD): Descemet membrane endothelial keratoplasty (DMEK).
  • Complex anterior segment anatomy, including aphakia, tube shunt devices, or prior vitrectomy: Descemet stripping automated endothelial keratoplasty (DSAEK) may be preferred over Descemet membrane endothelial keratoplasty (DMEK) because graft unfolding, positioning, and anterior-chamber tamponade can be more difficult; case selection remains individualized.
  • Combined cataract + Fuchs endothelial corneal dystrophy (FECD): Triple procedure (phacoemulsification + intraocular lens (IOL) implantation + Descemet membrane endothelial keratoplasty (DMEK)) provides a single intervention.
  • Alternatively staged: in selected eyes with mild Fuchs endothelial corneal dystrophy (FECD) without clinically significant edema and with adequate endothelial reserve, perform phacoemulsification first, monitor corneal function, and perform Descemet membrane endothelial keratoplasty (DMEK) if clinically significant decompensation develops; do not base the decision solely on a cutoff of fewer than 12 guttae.
Layer AffectedFirst LineIf Recurrent / DeepAvoid
Epithelial / basement membrane (BM)• Lubricants and a bandage contact lens for initial management • Epithelial debridement with or without phototherapeutic keratectomy (PTK) for refractory disease• Phototherapeutic keratectomy (PTK) for refractory recurrent erosions or visually significant superficial irregularity• Routine penetrating keratoplasty (PK) for typical superficial disease
Bowman's layer• Phototherapeutic keratectomy (PTK) may be used for visually significant disease• Select lamellar keratoplasty according to lesion depth and severity • Deep anterior lamellar keratoplasty (DALK) may be considered when disease is deeper or refractory• Routine penetrating keratoplasty (PK) for typical superficial disease
Anterior stroma• Phototherapeutic keratectomy (PTK) for superficial or anterior stromal disease • Lamellar keratoplasty when disease is deeper or phototherapeutic keratectomy is unsuitable• Keratoplasty for visually significant deep or recurrent disease when phototherapeutic keratectomy is unsuitable • Choose deep anterior lamellar keratoplasty (DALK) or penetrating keratoplasty (PK) according to posterior stromal and Descemet membrane involvement• Repeat phototherapeutic keratectomy (PTK) without pachymetry or residual-thickness analysis
Full stroma (macular corneal dystrophy (MCD))• Deep anterior lamellar keratoplasty (DALK) if Descemet membrane and endothelium are uninvolved• Penetrating keratoplasty (PK) when Descemet membrane involvement precludes a lamellar approach• Phototherapeutic keratectomy (PTK) for deep deposits
Endothelium (Fuchs endothelial corneal dystrophy (FECD))• Endothelial keratoplasty • Descemet membrane endothelial keratoplasty (DMEK) preferred for routine disease when technically suitable• Endothelial keratoplasty when opacity is predominantly endothelial • Consider penetrating keratoplasty (PK) when visually significant stromal scarring or opacity limits clearance• Routine penetrating keratoplasty (PK) when endothelial keratoplasty is suitable • Reserve it for extensive stromal scarring, severe opacity, or other situations unsuitable for endothelial keratoplasty
Endothelium (congenital hereditary endothelial dystrophy (CHED) - paediatric)• Endothelial keratoplasty, commonly Descemet stripping automated endothelial keratoplasty (DSAEK), for suitable pediatric eyes• Penetrating keratoplasty (PK) if endothelial keratoplasty is unsuitable or not feasible• Descemet membrane endothelial keratoplasty (DMEK) should not be treated as a universal option in very young children • Consider non-Descemet-stripping endothelial keratoplasty when Descemet membrane cannot be identified
Exam pearl
  • Recurrence after penetrating keratoplasty varies by dystrophy and duration of follow-up; it is common in Reis–Bücklers corneal dystrophy, granular corneal dystrophy, and lattice corneal dystrophy, and less common in macular corneal dystrophy.

9. Landmark Trials & Studies

Trial / StudyYearKey Finding
Cornea Donor Study (CDS)2008, 2013• 5-year graft survival 86% regardless of donor age • 10-year survival 77% vs 71% (12–65 vs 66–75 years, not statistically significant) • Older donors show slightly greater endothelial cell loss
Specular Microscopy Ancillary Study (SMAS)2008• Substantial endothelial cell loss after penetrating keratoplasty (PK) • Early postoperative endothelial cell density (ECD), particularly at 6 months, predicts subsequent graft failure
Moloney et al. - Descemetorhexis without grafting (DSO) + ripasudil2017• Ripasudil promoted corneal clearance in selected DSO failures • Supports Rho-associated protein kinase inhibition as an adjunct
Kinoshita et al., New England Journal of Medicine (NEJM)2018• Cultured human corneal endothelial-cell injection plus a Rho-associated protein kinase inhibitor increased endothelial cell density in 11/11 treated eyes • Corneal thickness below 630 μm occurred in 10/11 at 24 weeks • A two-line or greater visual-acuity improvement occurred in 9/11 at 24 weeks • Landmark regenerative approach
Price & Price Descemet membrane endothelial keratoplasty (DMEK) series2009 onwards• Descemet membrane endothelial keratoplasty (DMEK) achieved better visual outcomes than Descemet stripping automated endothelial keratoplasty (DSAEK) • Comparable endothelial cell loss
Eye Bank Association of America (EBAA)annual• Documents the shift from penetrating keratoplasty (PK) toward endothelial keratoplasty (EK) • In 2023, Descemet membrane endothelial keratoplasty (DMEK) surpassed Descemet stripping automated endothelial keratoplasty (DSAEK) in the United States • Descemet membrane endothelial keratoplasty (DMEK) was the most common domestic keratoplasty procedure in 2025
Avellino/granular corneal dystrophy type 2 (GCD2) laser in situ keratomileusis (LASIK) studies2000s• Laser in situ keratomileusis (LASIK) can markedly exacerbate Arg124His-associated granular corneal dystrophy type 2 (GCD2)/Avellino deposits • Supports genetic screening before refractive surgery in at-risk patients

10. Consultant-Level MCQ Traps

MCQ

Q1. Which listed dystrophy is incorrectly labeled as autosomal recessive?

MCQ

Q2. Which dystrophy thins the cornea?

MCQ

Q3. Preoperative genetic testing is most justified for:

MCQ

Q4. A 50-yr-old female with morning glare, central corneal thickness (CCT) 660 µm, central guttae, no oedema. Which is a reasonable initial management option?

MCQ

Q5. Which listed condition is associated with systemic amyloidosis?

MCQ

Q6. Which stain identifies macular dystrophy deposits?

MCQ

Q7. Recurrence after PK is highest with:

MCQ

Q8. Harboyan syndrome combines congenital hereditary endothelial dystrophy (CHED) with:

11. Viva Questions - Progressive Difficulty

Viva Questions - Progressive Difficulty
Q1

Define corneal dystrophy. List the IC3D groups.

Q2

Differentiate granular, lattice, and macular on slit lamp findings, stains, and inheritance.

Q3

A child presents with bilateral cloudy corneas at birth. How will you differentiate CHED from congenital glaucoma, congenital rubella, MPS, and birth trauma?

Q4

What is the role of PTK in TGFBI dystrophies, and what factors decide depth of ablation?

Q5

Walk me through your decision algorithm for a 60-year-old female with cataract, FECD (CCT 650 µm, ECC 900), no oedema. Triple procedure or staged? Justify.

Q6

Explain the molecular biology of TGFBI mutations and why R124C and R124H produce different phenotypes despite affecting the same residue.

Q7

Discuss the evolving role of Rho-kinase inhibitors and DSO in the FECD treatment paradigm. What patient profile is ideal for DSO?

Q8

How would you counsel a Korean patient with biopsy-proven Avellino dystrophy seeking refractive surgery?

12. Consultant-Level Extension Question

Consultant-level oral-exam question

A 32-year-old patient with Granular Corneal Dystrophy Type 2 (Avellino, R124H) underwent laser-assisted in situ keratomileusis (LASIK) 4 years ago and now presents with markedly worsened vision and dense central opacities along the laser-assisted in situ keratomileusis (LASIK) flap interface. Discuss your management strategy, the underlying molecular mechanism of accelerated deposition post-laser-assisted in situ keratomileusis (LASIK), and the role of preoperative genetic screening in refractive surgery practice.

Was this helpful?

Topic complete

Continue to another topic when you are ready.

Previous topic← Phlyctenular KeratitisNext topicFuchs Endothelial Corneal Dystrophy (FECD) & Pseudophakic Bullous Keratopathy (PBK)